Posted by Michael Wonder on 06 Apr 2018
Trelegy Ellipta approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD
5 April 2018 - Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), has been approved in Canada as the first and only inhaler product that combines three active molecules for the long-term, once daily, maintenance treatment of chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema in patients who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-adrenergic agonist.
Trelegy Ellipta is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist, delivered once-daily in GSK’s Ellipta dry powder inhaler.
Trelegy Ellipta availability is expected this June.
